首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
【24h】

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.

机译:严重急性呼吸综合征冠状病毒的结构蛋白对保护性免疫的贡献。

获取原文
获取原文并翻译 | 示例
       

摘要

We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.
机译:我们调查了严重急性呼吸系统综合症(SARS)冠状病毒(CoV)的结构蛋白对保护性免疫的贡献,方法是将它们分别和组合地从称为BHPIV3的重组副流感病毒(PIV)3型载体中表达。该载体可直接免疫呼吸道,即SARS传播,复制和疾病的主要部位。评估了BHPIV3 / SARS重组体在仓鼠中的免疫原性和保护功效,该仓鼠支持高水平的肺SARS-CoV复制。一次鼻内施用表达SARS-CoV峰值蛋白(S)的BHPIV3诱导了高滴度的SARS-CoV中和血清抗体,仅比SARS-CoV感染诱导的抗体低2倍。 S与其他两个推定的病毒粒子包膜蛋白(基质M和小包膜E蛋白)的表达不会增加中和抗体的应答。在没有S的情况下,M和E或核衣壳蛋白N的表达不会诱导可检测的血清SARS-CoV中和抗体应答。用表达S的BHPIV3进行的免疫提供了针对下呼吸道的SARS-CoV攻击的全面保护,以及对上呼吸道的部分保护。通过与M和E的共表达,这略有增强。在不存在S的情况下,M,E或N的表达不能提供可检测的保护。这些结果将结构蛋白中的S鉴定为唯一重要的SARS-CoV中和抗原和保护性抗原,表明在支持SARS-CoV有效复制的实验动物中,单次粘膜免疫具有高度保护性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号